IVOB - INVO Bioscience, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2156
-0.0099 (-4.41%)
At close: 3:42PM EST
Stock chart is not supported by your current browser
Previous Close0.2255
Open0.2300
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2110 - 0.2300
52 Week Range0.2060 - 0.5300
Volume74,123
Avg. Volume79,673
Market Cap35.226M
Beta (3Y Monthly)-0.93
PE Ratio (TTM)N/A
EPS (TTM)-0.0140
Earnings DateNov 14, 2019 - Nov 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.10
  • INVO Bioscience Reports Third Quarter 2019 Financial Results
    PR Newswire

    INVO Bioscience Reports Third Quarter 2019 Financial Results

    Company to Hold Investor Webcast on November 21, 2019 at 11:00am ET SARASOTA, Fla. , Nov. 14, 2019 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: IVOB), a medical device company focused on creating alternative ...

  • INVO Bioscience Expands its Presence in Eurasia with New Distribution Agreements to Commercialize the INVOcell In Vivo Fertilization System
    PR Newswire

    INVO Bioscience Expands its Presence in Eurasia with New Distribution Agreements to Commercialize the INVOcell In Vivo Fertilization System

    SARASOTA, Fla., Nov. 12, 2019 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, today announced it has entered into commercialization agreements in Eurasia, covering Turkey and Jordan. The agreements represent INVO Bioscience's expansion into Eurasia, a region with a growing middle-class population, yet experiencing a multi-decade decline in birth rate according to The World Bank.

  • INVO Bioscience Enters New Distribution Agreements in Africa to Commercialize the INVOcell In Vivo Fertilization System
    PR Newswire

    INVO Bioscience Enters New Distribution Agreements in Africa to Commercialize the INVOcell In Vivo Fertilization System

    SARASOTA, Fla., Nov. 7, 2019 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, today announced it has entered into commercialization agreements in the continent of Africa, covering Nigeria, Uganda, Sudan and Ethiopia, to distribute the revolutionary INVOcell system. The agreements represent INVO Bioscience's initial entry into the highly populated, yet in our opinion severely underserved infertility markets in Africa.

  • INVOcell Pioneers, Center for Assisted Reproduction, Named One of the 10 Best Fertility Clinics for Innovation
    PR Newswire

    INVOcell Pioneers, Center for Assisted Reproduction, Named One of the 10 Best Fertility Clinics for Innovation

    SARASOTA, Fla., Nov. 5, 2019 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, is pleased to announce that Parents magazine, a leading publication devoted to parenting from pregnancy to the school years, announced in its recent issue that the Center for Assisted Reproduction in Bedford and Fort Worth, Texas, owned by Drs. Kevin and Kathy Doody, has been judged to be one of the 10 Best Fertility Clinics for Innovation. The article discusses Drs. Kevin and Kathy Doody's championing of the INVOcell, including being a pilot clinic for the device in 2013. In 2013, the INVOcell device was piloted in a clinic in the United States by Drs. Kevin and Kathy Doody, who now practice at the Center For Assisted Reproduction (C.A.R.E.).

  • INVO Bioscience New CEO Sends Open Letter to Shareholders
    PR Newswire

    INVO Bioscience New CEO Sends Open Letter to Shareholders

    SARASOTA, Fla., Oct. 31, 2019 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of the FDA cleared INVOcell®, the world's only in vivo Intravaginal Culture System, is pleased to share an open letter to shareholders written by its newly appointed CEO. As INVO Bioscience's newly appointed CEO, it is with tremendous excitement that I write this letter. On behalf of the entire INVO Bioscience team, we sincerely appreciate your support, including those that have been with us for an extended period of time as well as our more recent shareholders.

  • INVO Bioscience Receives CE Mark for INVOcell Device Allowing the Company to Commercially Distribute Product in Europe
    PR Newswire

    INVO Bioscience Receives CE Mark for INVOcell Device Allowing the Company to Commercially Distribute Product in Europe

    SARASOTA, Fla., Oct. 24, 2019 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, today announced the receipt of a CE Mark for its INVOcell culture and retention device. The receipt of the CE Mark is the final requirement for INVO Bioscience to begin commercially distributing the revolutionary alternative to traditional IVF through the entire European Union.

  • INVO Bioscience Announces the Appointment of Steve Shum as Chief Executive Officer
    PR Newswire

    INVO Bioscience Announces the Appointment of Steve Shum as Chief Executive Officer

    SARASOTA, Fla., Oct. 14, 2019 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), a medical device company focused on creating alternative treatments for patients diagnosed with infertility & developers of INVOcell®, the first FDA-cleared Intravaginal Culture System, today announced the appointment of Steven Shum as the Company's Chief Executive Officer, effective immediately. Shum succeeds Kathleen Karloff, who is planning to retire after 12+ years with the Company as its CEO.

  • INVO Bioscience to Exhibit at Two Upcoming Scientific and Research Conferences
    PR Newswire

    INVO Bioscience to Exhibit at Two Upcoming Scientific and Research Conferences

    American Society for Reproductive Medicine 2019 Scientific Congress & Expo on October 12-16, 2019 20th World Congress of the International Society for In-Vitro Fertilization on October 24-26, 2019 SARASOTA, ...

  • INVO Bioscience Reports Record Second Quarter 2019 Financial Results with Revenue Increasing 498%
    PR Newswire

    INVO Bioscience Reports Record Second Quarter 2019 Financial Results with Revenue Increasing 498%

    SARASOTA, Fla. , Aug. 14, 2019 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: IVOB), a medical device company which was granted FDA clearance for its Intravaginal Culture System, INVOcell ® , today announced ...

  • INVO Bioscience Announces Recent Appointment of Pressly Ahammed as Director of International Business Development
    PR Newswire

    INVO Bioscience Announces Recent Appointment of Pressly Ahammed as Director of International Business Development

    SARASOTA, Fla., June 19, 2019 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), a medical device company which was granted FDA clearance for the first Intravaginal Culture System, INVOcell®, announced the recent appointment of Pressly Ahammed as INVO Bioscience's new Director of International Business Development. Ahammed will be responsible for developing the Company's international distribution channels in Europe, the Middle East, Africa and parts of Asia, and will report to Michael Campbell, chief operating officer of INVO Bioscience. Ahammed joins INVO Bioscience from Cooper Surgical, where he held a similar title focused on women's healthcare business development in Eastern Europe, the Middle East, Africa, and South and Central Asia.

  • INVO Bioscience's INVOcell Technology Featured in IVF Exhibit at the Science Museum in London
    PR Newswire

    INVO Bioscience's INVOcell Technology Featured in IVF Exhibit at the Science Museum in London

    SARASOTA, Fla., June 13, 2019 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), a medical device company which was granted FDA clearance for the first Intravaginal Culture System, INVOcell®, today announced that its INVOcell device is being featured in an in-vitro fertilization ("IVF") exhibit at the Science Museum in London. The main topic of the new display is the current frontiers and challenges of human reproduction, featuring the INVOcell Culture Device among other more traditional IVF procedures. Thanks to the advances in fertility treatment, including the first IVC (Intravaginal Culture) device in the world, the INVOcell Culture Device, millions more people have an innovative, cost-effective and proven new option that may result in the joy of creating a new family.

  • INVO Bioscience to Participate in the 35th Annual Meeting of the European Society of Human Reproduction and Embryology
    PR Newswire

    INVO Bioscience to Participate in the 35th Annual Meeting of the European Society of Human Reproduction and Embryology

    SARASOTA, Fla., June 5, 2019 /PRNewswire/ -- INVO Bioscience, Inc.® (IVOB), a medical device company which was granted FDA clearance for the first Intravaginal Culture System, INVOcell®, today announced it will participate at the 35th Annual Meeting of the European Society of Human Reproduction and Embryology ("ESHRE") in Vienna, Austria June 23 – 26, 2019. ESHRE is the leading European-based scientific trade organization devoted to research, education and advocacy relating to all facets of human reproduction and embryology.

  • INVO Bioscience Reports First Quarter 2019 Financial Results
    PR Newswire

    INVO Bioscience Reports First Quarter 2019 Financial Results

    MEDFORD, Mass. , May 15, 2019 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: IVOB), a medical device company which was granted FDA clearance for its Intravaginal Culture System, INVOcell™, today announced ...

  • ACCESSWIRE

    "The Digital Economy & World Markets"

    SAN FRANCISCO, CA / ACCESSWIRE / April 30, 2019 / Vista Partners ("Vista") has published April 2019's FREE Macroeconomic & Investment Monthly Newsletter, "The Digital Economy & World Markets." ...

  • INVO Bioscience Reports Record Fourth Quarter and Year End 2018 Financial Results
    PR Newswire

    INVO Bioscience Reports Record Fourth Quarter and Year End 2018 Financial Results

    MEDFORD, Mass., April 16, 2019 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), a medical device company which was granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced its fourth quarter and year end financial results for the periods ended December 31, 2018 as well as recent highlights. Closed exclusive U.S. licensing agreement with Ferring International Center S.A. the parent Company of Ferring Pharmaceuticals U.S. to commercialize the novel INVOcell™ system for use in the treatment of infertility.

  • ACCESSWIRE

    "Bull Market Hopping?"

    SAN FRANCISCO, CA / ACCESSWIRE / March 27, 2019 / Vista Partners ("Vista") has published March 2019's FREE Macroeconomic & Investment Monthly Newsletter, "Bull Market Hopping?" Vista's ...

  • INVO Bioscience Launches Embryology Center in the Bay Area to Support Dedicated INVOcell Clinic Being Developed by Dr. Aimee, the "Egg Whisperer"
    PR Newswire

    INVO Bioscience Launches Embryology Center in the Bay Area to Support Dedicated INVOcell Clinic Being Developed by Dr. Aimee, the "Egg Whisperer"

    MEDFORD, Mass. and SAN FRANCISCO, March 12, 2019 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), developers of the INVOcell intravaginal culture (IVC) system, today announced the launch of its first Company-owned embryology center in the Bay Area of California. The embryology center will act as the dedicated lab for famed fertility expert, Dr. Aimee D. Eyvazzadeh, MD, MPH, commonly known as the "Egg Whisperer," who will be opening a brand-new fertility treatment center dedicated to offering the INVOcell solution. Dr. Aimee's new center will be offering INVOcell, a novel fertility treatment that uses a woman's own body for the incubation of eggs and sperm during fertilization and early embryo development.

  • ACCESSWIRE

    "On Fed's Wings" Vista Partners Publishes February 2019's Macroeconomic & Investment Monthly Newsletter

    SAN FRANSISCO, CA / ACCESSWIRE / February 27, 2019 / Vista Partners ("Vista") has published February 2019's FREE Macroeconomic & Investment Monthly Newsletter, "On Fed's Wings." Vista's ...

  • INVO Bioscience Appoints Michael J. Campbell as COO & VP of Business Development
    PR Newswire

    INVO Bioscience Appoints Michael J. Campbell as COO & VP of Business Development

    MEDFORD, Mass. , Feb. 4, 2019 /PRNewswire/ -- INVO Bioscience, Inc. (OTC: IVOB), developers of the INVOcell intravaginal culture (IVC) system, today announced the appointment of Michael J. Campbell as ...

  • ACCESSWIRE

    Vista Partners January 2019 Monthly Macroeconomic and Investment Newsletter

    SAN FRANSICO, CA / ACCESSWIRE / January 30, 2019 / Vista Partners ("Vista") has published January 2019's FREE Macroeconomic & Investment Monthly Newsletter, "Global Expansion Slows." ...

  • INVO Bioscience Closes Exclusive U.S. Licensing Agreement with Ferring Pharmaceuticals to Commercialize the Novel INVOcell™ System for Use in the Treatment of Infertility
    PR Newswire

    INVO Bioscience Closes Exclusive U.S. Licensing Agreement with Ferring Pharmaceuticals to Commercialize the Novel INVOcell™ System for Use in the Treatment of Infertility

    MEDFORD, Mass., Jan. 14, 2019 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), developers of the INVOcell intravaginal culture (IVC) system, and Ferring Pharmaceuticals, a specialty biopharmaceutical group committed to helping people around the world build families and live better lives, announced today the closing of the previously announced exclusive U.S. commercialization rights agreement for INVOcell. Ferring will be responsible for all U.S. commercial activities for INVOcell. INVO Bioscience will be responsible for manufacturing and supplying the INVOcell devices to Ferring for commercial sales as well as performing a clinical study for label enhancement.